Ticker Symbol: NUVL
Nuvalent Inc - Class A
$27.50 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Currency:
USD
Asset
Type: Common Stock
CIK:0001861560
Company Profile
Nuvalent, Inc. is a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, Nuvalent develops innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
Website: www.nuvalent.com
CEO: N/A
Tags:
N/A
Pricing
Last Updated: October 13, 2023 03:00 PM EST
Previous Close: $57.99
Change:
-$2.12
(
-3.53%)
Days Range: $55.43 - $59.75
Beta: 1.83
52wk. High: $65.50
52wk. Low: $18.50
Ytd. Change 91.20%
50 Day Moving Average: $50.33
200 Day Moving Average: $42.98
Shares Outstanding: 51589540
Valuation
Market Cap: 299.2B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A